$4.22
-1.20 (-22.14%)
Open$5.80
Previous Close$5.42
Day High$5.81
Day Low$4.20
52W High$6.93
52W Low$1.87
Volume—
Avg Volume127.1K
Market Cap35.23M
P/E Ratio—
EPS$-5.31
SectorBiotechnology
Analyst Ratings
Strong Sell
6 analysts
Price Target
+923.7% upside
Current
$4.22
$4.22
Target
$43.20
$43.20
$28.55
$43.20 avg
$44.32
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 160.4K | 1.69M | 1.69M |
| Net Income | -28,311,794 | 118.4K | 113.8K |
| Profit Margin | -17,634.9% | 7.0% | 6.8% |
| EBITDA | -31,371,309 | 180.1K | 185.2K |
| Free Cash Flow | — | 113.7K | 84.7K |
| Rev Growth | — | -7.6% | +15.2% |
| Debt/Equity | 0.09 | 0.66 | 0.76 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $294.45 | -0.18% | 49.3 | 509.50B |
| AMGN | Amgen Inc | $467.06 | -0.22% | 26.5 | 248.84B |
| GILD | Gilead Sciences Inc | $167.95 | -1.05% | — | 208.28B |
| VRTX | Vertex Pharmaceuticals Inc | $542.62 | -0.81% | 34.5 | 137.12B |
| REGN | Regeneron Pharmaceuticals | $951.19 | -0.86% | 19.4 | 93.39B |
| ALNY | Alnylam Pharmaceuticals Inc | $156.65 | -2.00% | 7.7 | 20.98B |